"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 1999 | 2 | 2 | 4 |
| 2000 | 2 | 2 | 4 |
| 2001 | 1 | 4 | 5 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 2 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 1 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 2 | 4 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
-
Association of clinical outcomes and connectivity in awake versus asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2023 04 01; 138(4):1016-1027.
-
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022 06; 22(6):489-498.
-
The Entropy of Adaptively Segmented Beta Oscillations Predict Motor Improvement in Patients With Parkinson's Disease. IEEE Trans Biomed Eng. 2022 07; 69(7):2333-2341.
-
A case of treatable encephalopathy, developmental regression, and proximal tremor. Parkinsonism Relat Disord. 2021 12; 93:111-113.
-
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. J Neural Transm (Vienna). 2021 02; 128(2):273-277.
-
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
-
Distinct subthalamic coupling in the ON state describes motor performance in Parkinson's disease. Mov Disord. 2020 01; 35(1):91-100.
-
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
-
Dystonia. Nat Rev Dis Primers. 2018 09 20; 4(1):25.
-
A randomized controlled trial of levodopa in patients with Angelman syndrome. Am J Med Genet A. 2018 05; 176(5):1099-1107.